HotPennyStockNews.com is devoted to fetch you the most exclusive stocks in the market today. Apart from scanning the markets for the most underrated stocks. We propel those victors directly to your email inbox first ahead of the rest of the marketplace gets a prospect.
Los Angelas, CA -- (SBWIRE) -- 10/09/2012 -- Monster Worldwide (NYSE:MWW) is +0.76 - +10.41% from the previous close of $7.30. It traded between $7.21 - 8.16 with total traded volume of 3919570 shares. Keep a close eye on MWW, as the stock has been showing unusual moves over the past weeks. At Current market price,MWW has recovered +40.91% from its 52-week Low of 5.72 and has Pulled back -22.50% from its 52-week high of 10.40. Monster Worldwide (MWW) is another name which saw shares fall sharply on Friday. The shares fell off of a cliff, down $0.75 (9.32%) to close at $7.30/share, after news reports surfaced that private equity firms which had taken a look at the company for a buyout had walked away. At this point we wonder who is left to buy the company now…and if anyone, then the question is at what price. This certainly has not been a name to play for a buyout, even though the company has been actively shopping itself.
Should Investor Buy Or Sell This Stock Right Now: CHECK HERE
Eli Lilly and Com (NYSE:LLY) is very active today and traded between $47.76 - 50.94 with total traded volume of 28626088 shares. At a current price of 50.78, LLY is +2.55 - +5.29% from the previous close of $48.23. Moreover, At Current Market Price, LLY is in distance of +9.78% from its 50-day Moving Average price of $46.2577 and +18.53% from its 200-day Moving Average price of $42.8425. Eli Lilly (NYSE: LLY ) . The company has a number of drugs on the market, including the injectable insulin product Humalog and antidepressant Cymbalta. This stock has climbed about 20% year to date, and the stock jumped 5.29% today on news related to its Alzheimer's disease clinical trials. Eli Lilly's developmental drug solanezumab didn't meet the two primary endpoints set for the study, but the new data released today showed that the therapeutic was able to slow down memory loss in early-stage Alzheimer's patients by 34%. While these results aren't unequivocally positive, this market move reflected hope that solanezumab could eventually become a treatment option for Alzheimer's patients. Eli Lilly stated that it will consider the next steps for this drug in the coming weeks, but its road to FDA approval looks long and winding -- and could involve additional clinical trials. After today's increase, Eli Lilly is perched near its 52-week high, but investors should be on the lookout for upcoming clinical results related to this developmental medicine.
What's The Next Target Of LLY: FIND HERE
Shares of VIVUS, Inc. (NasdaqNM:VVUS) are trading at $20.44 and is -2.88% from its 50-day Moving Average price of $21.0466 and -12.19% from its 200-day Moving Average price of $23.2777. The average trading volume is 4861880 shares and its market capitalization is $2.051B. Shares of VIVUS (Nasdaq: VVUS ) have soared Monday by as much as 12% after the company scored a distribution deal with Express Scripts. Express Scripts has joined the Qsymia Certified Home Delivery Pharmacy Network, broadening VIVUS' distribution for its weight-loss pill that was launched just last month. Qsymia will be available through mail order. With Express Scripts being the country's largest pharmacy benefit manager, this deal is a boon for VIVUS.Qsymia is the first to enter the obesity drug market in 13 years, and investors are clearly excited about its potential to boost the top line. The deal today is a good sign that VIVUS has a leg up on Arena Pharmaceuticals and its competing Belviq drug for the time being. Belviq has already been cleared by the Food and Drug Administration, but hasn't been released into the market pending DEA clearance. For now, VIVUS has a first-mover advantage.
Can VVUS Touch $ 30.00 : FIND HERE
Polycom, Inc. (NasdaqNM:PLCM) is +0.81 - +8.52% from the previous close of $9.51. It traded between $9.39 - 10.35 with total traded volume of 4159778 shares. Keep a close eye on PLCM, as the stock has been showing unusual moves over the past weeks. At Current market price, PLCM has recovered +38.52% from its 52-week Low of 7.45 and has Pulled back -54.62% from its 52-week high of 22.74. The colleges, schools and universities that are part of the Career Education Corporation (“CEC”) family offer high-quality education to a diverse student population of more than 75,000 students across the world in a variety of career-oriented disciplines through online, on-ground and hybrid learning program offerings. The more than 90 campuses that serve these students are located throughout the United States and in France, the United Kingdom and Monaco, and offer doctoral, master’s, bachelor’s and associate degrees and diploma and certificate programs.
Need More Outlook About PLCM: CHECK HERE
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to loose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-321-1250 (International)